Vir begins dosing participants in Phase 2 clinical trial for new type of flu shot


Vir Biotechnology Inc. VIR, +4.50% said Tuesday that it began dosing participants in a Phase 2 clinical trial evaluating its experimental monoclonal antibody to prevent illness from influenza A. The investigational therapy is an intramuscular dose that has been designed to prevent seasonal flu and influenza A, which has previously caused flu pandemics, including the H1N1 pandemic in 2009. The randomized, double-blind, placebo-controlled study will enroll 3,0000 healthy adults, and the first batch of data from the trial is expected to be available in mid-2023. Vir’s stock has declined 48.4% this year, while the S&P 500 SPX, +2.65% is down 24.9%.

This article was originally published by Read the original article here.

Previous articleMarket Snapshot: Dow futures up over 200 points on optimism over earnings reports
Next articleGoldman Sachs per-share earnings fall but exceed consensus estimate


Please enter your comment!
Please enter your name here